 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
| 123» |
- | vibostolimab/pembrolizumab (MK-7684A) / Merck (MSD), favezelimab/pembrolizumab (MK-4280A) / Merck (MSD)
Enrollment change, Trial withdrawal, Tumor mutational burden: A Study of Pembrolizumab in Combination With Investigational Agents in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01B/LIGHTBEAM-U01) (clinicaltrials.gov) - Jan 16, 2025
P1/2, N=0, Withdrawn, Sponsor: Merck Sharp & Dohme LLC
N=60 --> 0 | Recruiting --> Withdrawn
- ||| Keytruda (pembrolizumab) / Merck (MSD)
Enrollment closed: Study of Pembrolizumab (MK-3475) and Pembrolizumab With Other Investigational Agents in Participants With High Risk Non-muscle Invasive Bladder Cancer (MK-3475-057/KEYNOTE-057) (clinicaltrials.gov) - Jan 7, 2025
P2, N=320, Active, not recruiting, Sponsor: Merck Sharp & Dohme LLC
N=60 --> 0 | Recruiting --> Withdrawn Recruiting --> Active, not recruiting
- favezelimab/pembrolizumab (MK-4280A) / Merck (MSD)
Co-formulated favezelimab plus pembrolizumab versus standard-of-care in previously treated, PD-L1-positive metastatic colorectal cancer: The phase 3, randomized KEYFORM-007 study. (Level 1, West Hall; Poster Bd #: K8) - Dec 17, 2024 - Abstract #ASCOGI2025ASCO_GI_933;
P3
Clinical Trial Registration Number: NCT05064059. The abstract will be released to the public on January 25, 2025 at 3:00 PM UTC
- || quavonlimab/pembrolizumab (MK-1308A) / Merck (MSD), Keytruda (pembrolizumab) / Merck (MSD)
Trial completion date, Trial primary completion date, Mismatch repair, Metastases: Evaluation of Co-formulated Pembrolizumab/Quavonlimab (MK-1308A) Versus Other Treatments in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer (CRC) (MK-1308A-008/KEYSTEP-008) (clinicaltrials.gov) - Dec 13, 2024
P2, N=320, Active, not recruiting, Sponsor: Merck Sharp & Dohme LLC
The abstract will be released to the public on January 25, 2025 at 3:00 PM UTC Trial completion date: Nov 2025 --> Jun 2027 | Trial primary completion date: Oct 2025 --> Jun 2026
- favezelimab/pembrolizumab (MK-4280A) / Merck (MSD)
COFORMULATED FAVEZELIMAB AND PEMBROLIZUMAB (PEMBRO) VERSUS CHEMOTHERAPY (CHEMO) IN PATIENTS (PTS) WITH RELAPSED OR REFRACTORY (R/R) CLASSICAL HODGKIN LYMPHOMA (CHL) REFRACTORY TO ANTI (Gro) - Oct 31, 2024 - Abstract #ISHL2024ISHL_179;
P3
Pts must also have been ineligible for brentuximab vedotin (BV), relapsed on or whose disease failed to respond to BV, or discontinued BV due to toxicity. Approximately 360 pts will be enrolled and randomly assigned 1:1 to receive coformulated favezelimab 800 mg/pembrolizumab 200 mg IV Q3W or physician's choice of chemo (gemcitabine, 800
- || Keytruda (pembrolizumab) / Merck (MSD), favezelimab/pembrolizumab (MK-4280A) / Merck (MSD)
Trial completion date, Metastases: KEYFORM-007: A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007)-China Extension Study (clinicaltrials.gov) - Oct 30, 2024
P3, N=94, Active, not recruiting, Sponsor: Merck Sharp & Dohme LLC
Approximately 360 pts will be enrolled and randomly assigned 1:1 to receive coformulated favezelimab 800 mg/pembrolizumab 200 mg IV Q3W or physician's choice of chemo (gemcitabine, 800 Trial completion date: Nov 2025 --> Feb 2025
- ||| Keytruda (pembrolizumab) / Merck (MSD), favezelimab/pembrolizumab (MK-4280A) / Merck (MSD)
Trial completion date, Metastases: KEYFORM-007: A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007) (clinicaltrials.gov) - Oct 30, 2024
P3, N=505, Active, not recruiting, Sponsor: Merck Sharp & Dohme LLC
Trial completion date: Nov 2025 --> Feb 2025 Trial completion date: Nov 2025 --> Feb 2025
- ||| Enrollment open, Enrollment change, Trial completion date, Trial primary completion date, Combination therapy, Monotherapy: Safety and Efficacy Study of Investigational Agents as Monotherapy or in Combination With Pembrolizumab (MK-3475) for the Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in Need of Second-Line Therapy (MK-3475-B98/KEYNOTE-B98) (clinicaltrials.gov) - Oct 16, 2024
P1/2, N=110, Recruiting, Sponsor: Merck Sharp & Dohme LLC
Trial completion date: Nov 2025 --> Feb 2025 Active, not recruiting --> Recruiting | N=80 --> 110 | Trial completion date: Nov 2026 --> Nov 2029 | Trial primary completion date: Nov 2026 --> May 2026
- ||| vibostolimab/pembrolizumab (MK-7684A) / Merck (MSD), favezelimab/pembrolizumab (MK-4280A) / Merck (MSD)
Enrollment open, Tumor mutational burden: A Study of Pembrolizumab in Combination With Investigational Agents in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01B/LIGHTBEAM-U01) (clinicaltrials.gov) - Jul 17, 2024
P1/2, N=80, Recruiting, Sponsor: Merck Sharp & Dohme LLC
Active, not recruiting --> Recruiting | N=80 --> 110 | Trial completion date: Nov 2026 --> Nov 2029 | Trial primary completion date: Nov 2026 --> May 2026 Not yet recruiting --> Recruiting
- || Keytruda (pembrolizumab) / Merck (MSD), favezelimab/pembrolizumab (MK-4280A) / Merck (MSD)
Trial completion date, Metastases: KEYFORM-007: A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007)-China Extension Study (clinicaltrials.gov) - Jul 11, 2024
P3, N=94, Active, not recruiting, Sponsor: Merck Sharp & Dohme LLC
Not yet recruiting --> Recruiting Trial completion date: Jul 2025 --> Nov 2025
- ||| quavonlimab/pembrolizumab (MK-1308A) / Merck (MSD), Keytruda (pembrolizumab) / Merck (MSD)
Enrollment closed, Mismatch repair, Metastases: Evaluation of Co-formulated Pembrolizumab/Quavonlimab (MK-1308A) Versus Other Treatments in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer (CRC) (MK-1308A-008/KEYSTEP-008) (clinicaltrials.gov) - Jun 26, 2024
P2, N=320, Active, not recruiting, Sponsor: Merck Sharp & Dohme LLC
Trial completion date: Jul 2025 --> Nov 2025 Recruiting --> Active, not recruiting
- || Keytruda (pembrolizumab) / Merck (MSD)
Enrollment closed: KEYMAKER-U06 substudy 06A: A Study of Combination Therapies With or Without Pembrolizumab (MK-3475) and/or Chemotherapy in Participants With Advanced Esophageal Cancer (MK-3475-06A) (clinicaltrials.gov) - Jun 5, 2024
P1/2, N=120, Active, not recruiting, Sponsor: Merck Sharp & Dohme LLC
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- favezelimab (MK-4280) / Merck (MSD), Keytruda (pembrolizumab) / Merck (MSD)
PEMBROLIZUMAB PLUS THE ANTI (Poster Area (Hall 7)) - May 15, 2024 - Abstract #EHA2024EHA_1944;
P1/2
Recruiting --> Active, not recruiting In this updated analysis, pembrolizumab plus favezelimab continued to demonstrate manageable safety andsustained antitumor activity in pts with anti
- favezelimab (MK-4280) / Merck (MSD), Keytruda (pembrolizumab) / Merck (MSD)
PEMBROLIZUMAB PLUS THE ANTI (Poster Area (Hall 7)) - May 15, 2024 - Abstract #EHA2024EHA_1943;
P1/2, P3
In this updated analysis, pembrolizumab plus favezelimab continued to demonstrate manageable safety andsustained antitumor activity in pts with anti In this updated analysis, pembrolizumab plus favezelimab continued to demonstrate manageable safety andantitumor activity in pts with heavily pretreated anti
- |||| vibostolimab/pembrolizumab (MK-7684A) / Merck (MSD), favezelimab/pembrolizumab (MK-4280A) / Merck (MSD)
New P1/2 trial, Tumor mutational burden: A Study of Pembrolizumab in Combination With Investigational Agents in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01B/LIGHTBEAM-U01) (clinicaltrials.gov) - May 1, 2024
P1/2, N=80, Not yet recruiting, Sponsor: Merck Sharp & Dohme LLC
- favezelimab (MK-4280) / Merck (MSD), Keytruda (pembrolizumab) / Merck (MSD)
A phase 1/2 study of favezelimab in combination with pembrolizumab for heavily pretreated anti (Hall A; Poster Bd #: 39) - Apr 24, 2024 - Abstract #ASCO2024ASCO_2391;
P1/2, P3
In this updated analysis, pembrolizumab plus favezelimab continued to demonstrate manageable safety andantitumor activity in pts with heavily pretreated anti After additional follow-up, favezelimab + pembrolizumab continued to demonstrate manageable safety and antitumor activity in pts with heavily pretreated anti
- favezelimab (MK-4280) / Merck (MSD), Keytruda (pembrolizumab) / Merck (MSD)
A phase 1/2 study of favezelimab in combination with pembrolizumab for anti (Hall A; Poster Bd #: 38) - Apr 24, 2024 - Abstract #ASCO2024ASCO_2390;
P1/2
After additional follow-up, favezelimab + pembrolizumab continued to demonstrate manageable safety and antitumor activity in pts with heavily pretreated anti With additional follow-up, favezelimab plus pembrolizumab continued to demonstrate sustained antitumor activity and manageable safety in pts with anti
- ||| Keytruda (pembrolizumab) / Merck (MSD)
Enrollment closed: Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A) (clinicaltrials.gov) - Apr 18, 2024
P1/2, N=400, Active, not recruiting, Sponsor: Merck Sharp & Dohme LLC
With additional follow-up, favezelimab plus pembrolizumab continued to demonstrate sustained antitumor activity and manageable safety in pts with anti Recruiting --> Active, not recruiting
- | Phase classification, Combination therapy, Monotherapy: Safety and Efficacy Study of Investigational Agents as Monotherapy or in Combination With Pembrolizumab (MK-3475) for the Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in Need of Second-Line Therapy (MK-3475-B98/KEYNOTE-B98) (clinicaltrials.gov) - Apr 4, 2024
P1/2, N=80, Active, not recruiting, Sponsor: Merck Sharp & Dohme LLC
Recruiting --> Active, not recruiting Phase classification: P1b/2 --> P1/2
- ||| Trial completion, Monotherapy, Metastases: Study of Favezelimab (MK-4280) as Monotherapy and in Combination With Pembrolizumab (MK-3475) With or Without Chemotherapy or Lenvatinib (MK-7902) AND Favezelimab/Pembrolizumab (MK-4280A) as Monotherapy in Adults With Advanced Solid Tumors (MK-4280-001) (clinicaltrials.gov) - Mar 27, 2024
P1, N=482, Completed, Sponsor: Merck Sharp & Dohme LLC
Phase classification: P1b/2 --> P1/2 Active, not recruiting --> Completed
- Keytruda (pembrolizumab) / Merck (MSD)
Results from KEYNOTE-B98: A phase 1b/2 study of pembrolizumab plus investigational agents in patients with anti-PD-(L)1-refractory extensive-stage small-cell lung cancer (ES-SCLC) (Section 48) - Mar 5, 2024 - Abstract #AACR2024AACR_7888;
Active, not recruiting --> Completed Abstract is embargoed at this time.
- ||| vibostolimab/pembrolizumab (MK-7684A) / Merck (MSD), favezelimab/pembrolizumab (MK-4280A) / Merck (MSD)
Enrollment closed: KEYMAKER-U04 Substudy: A Study of Efficacy and Safety of Pembrolizumab Plus Enfortumab Vedotin (EV) +/- Investigational Agents in First-Line Metastatic Urothelial Carcinoma (mUC) (MK-3475-04B/KEYMAKER-U04) (clinicaltrials.gov) - Feb 19, 2024
P1/2, N=390, Active, not recruiting, Sponsor: Merck Sharp & Dohme LLC
Abstract is embargoed at this time. Recruiting --> Active, not recruiting
- ||| Keytruda (pembrolizumab) / Merck (MSD), favezelimab/pembrolizumab (MK-4280A) / Merck (MSD)
Trial completion date, Metastases: KEYFORM-007: A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007) (clinicaltrials.gov) - Feb 15, 2024
P3, N=432, Active, not recruiting, Sponsor: Merck Sharp & Dohme LLC
Recruiting --> Active, not recruiting Trial completion date: Nov 2024 --> Nov 2025
- |||| Lenvima (lenvatinib) / Eisai, Merck (MSD), Lynparza (olaparib) / Merck (MSD), AstraZeneca, favezelimab/pembrolizumab (MK-4280A) / Merck (MSD)
Trial completion date, Trial primary completion date: Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587) (clinicaltrials.gov) - Feb 15, 2024
P3, N=3500, Recruiting, Sponsor: Merck Sharp & Dohme LLC
Trial completion date: Nov 2024 --> Nov 2025 Trial completion date: May 2028 --> Aug 2043 | Trial primary completion date: May 2028 --> Aug 2043
- Lenvima (lenvatinib) / Eisai, Merck (MSD), favezelimab/pembrolizumab (MK-4280A) / Merck (MSD)
A Randomized, Double-Blind, Phase 2 Study of MK-4280A (Coformulation of Favezelimab and Pembrolizumab) Plus Lenvatinib vs Pembrolizumab Plus Lenvatinib in Patients With Previously Treated Mismatch Repair () - Feb 3, 2024 - Abstract #SGO2024SGO_626;
- favezelimab/pembrolizumab (MK-4280A) / Merck (MSD)
A Randomized, Double-Blind, Phase 2 Study of Perioperative MK-4280A (Coformulation of Favezelimab and Pembrolizumab) vs Pembrolizumab in Patients With Resectable Cutaneous Squamous Cell Carcinoma (cSCC) (JW Marriott Desert Ridge Grand Canyon 6-8; Poster Screen #8) - Jan 24, 2024 - Abstract #MHNCS2024MHNCS_292;
P2
In the phase 3 RELATIVITY-047 study, 1L relatlimab (anti?LAG3 antibody) + nivolumab (nivo; anti?PD-1 antibody) prolonged PFS vs nivo in patients (pts) with unresectable advanced melanoma; and a phase 2 study showed high pathologic complete response (pCR) rate in resectable disease... TBD
- Lenvima (lenvatinib) / Eisai, Merck (MSD), favezelimab/pembrolizumab (MK-4280A) / Merck (MSD)
A Randomized, Double-Blind, Phase 2 Study Of MK-4280A (Coformulation Of Favezelimab And Pembrolizumab) Plus Lenvatinib Vs Pembrolizumab Plus Lenvatinib In Patients With Previously Treated Mismatch Repair (Exhibition hall) - Jan 18, 2024 - Abstract #ESGO2024ESGO_753;
P2
Secondary endpoints are OS; PFS and duration of response per RECIST v1.1 by investigator assessment; and safety. Enrolment began in September 2023.Results TBDConclusion TBD
- favezelimab (MK-4280) / Merck (MSD), favezelimab/pembrolizumab (MK-4280A) / Merck (MSD), vibostolimab (MK-7684) / Merck (MSD)
Screen D: Trials in progress Phase 2 KEYNOTE-057 cohort C: Coformulations of pembrolizumab (pembro) and favezelimab or vibostolimab for patients with bacillus Calmette-Gu (EGPT) - Jan 15, 2024 - Abstract #EAU2024EAU_2650;
- |||| Keytruda (pembrolizumab) / Merck (MSD), favezelimab/pembrolizumab (MK-4280A) / Merck (MSD)
Trial primary completion date, Metastases: KEYFORM-007: A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007) (clinicaltrials.gov) - Jan 8, 2024
P3, N=432, Active, not recruiting, Sponsor: Merck Sharp & Dohme LLC
Enrolment began in September 2023.Results TBDConclusion TBD Trial primary completion date: Feb 2024 --> Aug 2024
- ||||| Lenvima (lenvatinib) / Eisai, Merck (MSD), Lynparza (olaparib) / Merck (MSD), AstraZeneca, favezelimab/pembrolizumab (MK-4280A) / Merck (MSD)
Enrollment change: Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587) (clinicaltrials.gov) - Dec 27, 2023
P3, N=3500, Recruiting, Sponsor: Merck Sharp & Dohme LLC
Trial primary completion date: Feb 2024 --> Aug 2024 N=2300 --> 3500
- || Enrollment closed, Combination therapy: KEYMAKER-U02 Substudy 02C: Substudy 02C: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Stage III Melanoma Who Are Candidates for Neoadjuvant Therapy (MK-3475-02C/KEYMAKER-U02) (clinicaltrials.gov) - Dec 22, 2023
P1/2, N=90, Active, not recruiting, Sponsor: Merck Sharp & Dohme LLC
N=2300 --> 3500 Recruiting --> Active, not recruiting
- | Keytruda (pembrolizumab) / Merck (MSD)
Phase classification: KEYMAKER-U03B: Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B) (clinicaltrials.gov) - Dec 19, 2023
P1/2, N=370, Active, not recruiting, Sponsor: Merck Sharp & Dohme LLC
Recruiting --> Active, not recruiting Phase classification: P1b/2 --> P1/2
- || Keytruda (pembrolizumab) / Merck (MSD)
P2 data, Review, Journal, Metastases: KEYSTEP-008: phase II trial of pembrolizumab-based combination in MSI-H/dMMR metastatic colorectal cancer. (Pubmed Central) - Dec 17, 2023
P2
Phase classification: P1b/2 --> P1/2 Here we describe the design and rationale for the open-label, randomized, phase II KEYSTEP-008 trial, which will evaluate the efficacy and safety of pembrolizumab-based combination therapy compared with pembrolizumab monotherapy in chemotherapy-refractory (cohort
- favezelimab (MK-4280) / Merck (MSD), favezelimab/pembrolizumab (MK-4280A) / Merck (MSD), vibostolimab (MK-7684) / Merck (MSD)
Pembrolizumab with favezelimab or vibostolimab for patients with bacillus Calmette-Gu (Level 1, West Hall; Poster Bd # M19) - Dec 13, 2023 - Abstract #ASCOGU2024ASCO_GU_674;
P2
Enrollment is ongoing in Asia, Australia, Europe, North America, and South America. Clinical trial information: NCT02625961.
- | Keytruda (pembrolizumab) / Merck (MSD)
Phase classification: Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A) (clinicaltrials.gov) - Nov 18, 2023
P1/2, N=400, Recruiting, Sponsor: Merck Sharp & Dohme LLC
Clinical trial information: NCT02625961. Phase classification: P1b/2 --> P1/2
- |||| favezelimab/pembrolizumab (MK-4280A) / Merck (MSD)
Trial primary completion date: KEYFORM-008: A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Physician's Choice Chemotherapy in PD-(L)1-refractory, Relapsed or Refractory Classical Hodgkin Lymphoma (MK-4280A-008) (clinicaltrials.gov) - Nov 15, 2023
P3, N=360, Recruiting, Sponsor: Merck Sharp & Dohme LLC
Phase classification: P1b/2 --> P1/2 Trial primary completion date: Jun 2031 --> May 2027
- favezelimab (MK-4280) / Merck (MSD), Keytruda (pembrolizumab) / Merck (MSD)
Favezelimab in Combination with Pembrolizumab in Patients with Heavily Pretreated Anti (SDCC - Halls G-H) - Nov 3, 2023 - Abstract #ASH2023ASH_5881;
P1/2, P3
Trial primary completion date: Jun 2031 --> May 2027 After additional follow-up, the combination of favezelimab + pembrolizumab continued to demonstrate manageable safety and antitumor activity in patients with heavily pretreated anti
- favezelimab/pembrolizumab (MK-4280A) / Merck (MSD)
Open-Label, Randomized, Phase 3 Study of Coformulated Favezelimab and Pembrolizumab Versus Chemotherapy in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma Refractory to Anti (SDCC - Halls G-H) - Nov 3, 2023 - Abstract #ASH2023ASH_2931;
P3
After additional follow-up, the combination of favezelimab + pembrolizumab continued to demonstrate manageable safety and antitumor activity in patients with heavily pretreated anti In addition, patients should also have been ineligible for brentuximab vedotin (BV), relapsed or failed to respond to BV or discontinued BV due to toxicity...Approximately 360 patients will be enrolled and randomly assigned 1:1 to receive coformulated favezelimab 800 mg and pembrolizumab 200 mg intravenously (IV) every 3 weeks (Q3W) or physician
- favezelimab (MK-4280) / Merck (MSD), Keytruda (pembrolizumab) / Merck (MSD)
Favezelimab (anti (SDCC - Halls G-H) - Nov 3, 2023 - Abstract #ASH2023ASH_2145;
P1/2
Analyses are underway to identify biomarkers predictive of response to the combination of favezelimab and pembrolizumab. The safety profile was manageable and consistent with that observed in other cohorts in the study.
- favezelimab (MK-4280) / Merck (MSD), Keytruda (pembrolizumab) / Merck (MSD)
Favezelimab in Combination with Pembrolizumab in Patients with Anti (SDCC - Halls G-H) - Nov 3, 2023 - Abstract #ASH2023ASH_2112;
P1/2
The safety profile was manageable and consistent with that observed in other cohorts in the study. With additional follow-up, the combination of favezelimab and pembrolizumab continued to demonstrate sustained antitumor activity and manageable safety in patients with anti
- ||| Keytruda (pembrolizumab) / Merck (MSD)
Enrollment closed: KEYMAKER-U03B: Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B) (clinicaltrials.gov) - Nov 2, 2023
P1b/2, N=370, Active, not recruiting, Sponsor: Merck Sharp & Dohme LLC
With additional follow-up, the combination of favezelimab and pembrolizumab continued to demonstrate sustained antitumor activity and manageable safety in patients with anti Recruiting --> Active, not recruiting
- ||| Keytruda (pembrolizumab) / Merck (MSD), favezelimab/pembrolizumab (MK-4280A) / Merck (MSD)
Enrollment open, Pan tumor: KeyForm-010: Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010) (clinicaltrials.gov) - Oct 10, 2023
P2, N=160, Recruiting, Sponsor: Merck Sharp & Dohme LLC
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- favezelimab (MK-4280) / Merck (MSD), favezelimab/pembrolizumab (MK-4280A) / Merck (MSD)
External reproducibility of PD-L1 IHC 22C3 pharmDx for colorectal carcinoma specimens at CPS ? 1 cutoff (Exhibit Hall B) - Sep 27, 2023 - Abstract #SITC2023SITC_379;
P1
Not yet recruiting --> Recruiting 1 Recent results from MK4280
- |||| Keytruda (pembrolizumab) / Merck (MSD), favezelimab/pembrolizumab (MK-4280A) / Merck (MSD)
New P2 trial, Pan tumor: KeyForm-010: Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010) (clinicaltrials.gov) - Sep 14, 2023
P2, N=160, Not yet recruiting, Sponsor: Merck Sharp & Dohme LLC
- |||| Keytruda (pembrolizumab) / Merck (MSD), favezelimab/pembrolizumab (MK-4280A) / Merck (MSD)
Enrollment closed, Metastases: KEYFORM-007: A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007)-China Extension Study (clinicaltrials.gov) - Jul 25, 2023
P3, N=94, Active, not recruiting, Sponsor: Merck Sharp & Dohme LLC
1 Recent results from MK4280 Recruiting --> Active, not recruiting
- |||| vibostolimab/pembrolizumab (MK-7684A) / Merck (MSD), favezelimab/pembrolizumab (MK-4280A) / Merck (MSD)
Enrollment open: KEYMAKER-U04 Substudy: A Study of Efficacy and Safety of Pembrolizumab Plus Enfortumab Vedotin (EV) +/- Investigational Agents in First-Line Metastatic Urothelial Carcinoma (mUC) (MK-3475-04B/KEYMAKER-U04) (clinicaltrials.gov) - Jun 7, 2023
P1/2, N=390, Recruiting, Sponsor: Merck Sharp & Dohme LLC
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- favezelimab (MK-4280) / Merck (MSD), Keytruda (pembrolizumab) / Merck (MSD)
ESTIMATING THE RELATIVE EFFICACY OF FAVEZELIMAB WHEN USED IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH PD-1 (Poster area) - May 12, 2023 - Abstract #EHA2023EHA_1336;
Not yet recruiting --> Recruiting In this post hoc analysis, the combination of favezelimab + pembrolizumab was associated with a higher ORR and deeper responses than pembrolizumab monotherapy in patients with PD-1
- favezelimab (MK-4280) / Merck (MSD), Keytruda (pembrolizumab) / Merck (MSD)
UPDATED RESULTS FROM AN OPEN-LABEL PHASE 1/2 STUDY OF FAVEZELIMAB IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA AFTER ANTI (Poster area) - May 12, 2023 - Abstract #EHA2023EHA_1328;
P1/2
In this post hoc analysis, the combination of favezelimab + pembrolizumab was associated with a higher ORR and deeper responses than pembrolizumab monotherapy in patients with PD-1 The combination of favezelimab plus pembrolizumab continued to demonstrate antitumor activity and manageable safety in pts with R/R cHL whose disease progressed following anti
- favezelimab (MK-4280) / Merck (MSD), Keytruda (pembrolizumab) / Merck (MSD)
UPDATED RESULTS FROM AN OPEN-LABEL PHASE 1/2 STUDY OF FAVEZELIMAB IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH ANTI (Poster area) - May 12, 2023 - Abstract #EHA2023EHA_1325;
P1/2
The combination of favezelimab plus pembrolizumab continued to demonstrate antitumor activity and manageable safety in pts with R/R cHL whose disease progressed following anti Favezelimab + pembrolizumab continued to demonstrate sustained antitumor activity and acceptable safety in anti
- ||||| vibostolimab/pembrolizumab (MK-7684A) / Merck (MSD), favezelimab/pembrolizumab (MK-4280A) / Merck (MSD)
New P1/2 trial: KEYMAKER-U04 Substudy: A Study of Efficacy and Safety of Pembrolizumab Plus Enfortumab Vedotin (EV) +/- Investigational Agents in First-Line Metastatic Urothelial Carcinoma (mUC) (MK-3475-04B/KEYMAKER-U04) (clinicaltrials.gov) - May 6, 2023
P1/2, N=390, Not yet recruiting, Sponsor: Merck Sharp & Dohme LLC